The Flow Cytometry Facility (FCF) is a Shared Resource that provides Cancer Center investigators access to high quality, cost effective flow cytometry services and technology. By providing these services and the scientific expertise necessary to effectively use this technology, the facility serves to enhance the scope and quality of cancer research performed at the University. With state of the art instrumentation, the facility offers high speed 4 way cell sorting and cloning, complex multicolor analytical services, multiplexing assays for soluble analytes, and imaging flow cytometry. This instrumentation is compatible with a wide variety of flow cytometric applications such as subpopulation identification/quantification, molecular detection (using labeled antibodies or other ligands or fluorescent protein reporter molecules), measurement of DNA and RNA content for cell cycle analysis, apoptosis, transcriptional activity, intracellular ion concentration (e.g. Ca++), cell viability, membrane potential, microarrays, and bead based immunoassays. In addition to the instrumentation, the highly experienced staff of the FCF provides consultation in experimental design, sample preparation and data analysis. Researchers have the option, once trained, of performing their own analysis or utilizing the expertise of the facility's staff to run their samples for them. Specialized training classes are offered for those researchers who wish to better understand the principles and techniques employed in this technology and prefer to directly acquire and/or analyze their own samples. The services and expertise offered by the FCF play a key role in the study of many types of cancer, especially hematological malignancies, as well as immune responses to cancers.
Flow cytometry is a mainstay of research on the immune system, and has now broadened its utility to all aspects of cancer research where analysis of single cells is important. As we learn more about the heterogeneity of tumors, this becomes increasingly critical for modern cancer research.
|Melssen, Marit; Slingluff Jr, Craig L (2017) Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 47:85-92|
|Bullock, Timothy Nj (2017) TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines. Curr Opin Immunol 47:70-77|
|Scalici, Jennifer M; Arapovic, Sanja; Saks, Erin J et al. (2017) Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer 123:977-984|
|Shukla, Girja S; Olson, Walter C; Pero, Stephanie C et al. (2017) Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. J Transl Med 15:180|
|Keim-Malpass, Jessica; Mitchell, Emma M; DeGuzman, Pamela B et al. (2017) Legislative activity related to the human papillomavirus (HPV) vaccine in the United States (2006-2015): a need for evidence-based policy. Risk Manag Healthc Policy 10:29-32|
|Mills, Anne M; Paquette, Cherie; Terzic, Tatjana et al. (2017) CK7 Immunohistochemistry as a Predictor of CIN1 Progression: A Retrospective Study of Patients From the Quadrivalent HPV Vaccine Trials. Am J Surg Pathol 41:143-152|
|Rohani, Ali; Moore, John H; Kashatus, Jennifer A et al. (2017) Label-Free Quantification of Intracellular Mitochondrial Dynamics Using Dielectrophoresis. Anal Chem 89:5757-5764|
|Wages, N A; Slingluff Jr, C L; Petroni, G R (2017) Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies. Ann Oncol 28:696-701|
|O'Brien, Carleigh A; Overall, Christopher; Konradt, Christoph et al. (2017) CD11c-Expressing Cells Affect Regulatory T Cell Behavior in the Meninges during Central Nervous System Infection. J Immunol 198:4054-4061|
|Bullock, Timothy Nj (2017) Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr Opin Immunol 45:82-88|
Showing the most recent 10 out of 472 publications